May 7, 2026 - For the first time, every therapeutic company presenting at the Food Allergy Fund Summit is now in human clinical trials.

This marks a major inflection point for food allergy research.

March 19, 2026 - New data presented at this year's American Academy of Allergy, Asthma & Immunology - AAAAI Annual Meeting delivers a wake-up call for anyone working in food allergy.

75.5% of children with food allergy had multiple current food allergies.

February 13, 2026 - A landmark new study from McMaster University—spanning 2.8 million children and 190 studies worldwide—confirms what many of us in the food allergy community have long understood.

February 11, 2026 - The Food Allergy Fund was the earliest supporter of David A. Hill, MD, PhD and The Hill Lab’s work on eosinophilic esophagitis at Children's Hospital of Philadelphia and University of Pennsylvania School of Medicine.

January 31, 2026 - With plans to review harmful additives, expand front-of-package and online labeling, strengthen infant food standards, and improve formula access, the FDA is signaling a shift toward prevention and transparency in its 2026 agenda.

January 27, 2026 - For decades, allergic and autoimmune diseases were often treated as secondary priorities in federal research agendas. Now, theNational Institute of Allergy and Infectious Diseases (NIAID) is elevating immunology—alongside infectious diseases—as a core pillar for improving health outcomes. The National Institutes of Health Director Jay Bhattacharya and NIAID Acting Director Dr. Jeffery Taubenberger shared this vision at the FAF Leadership Forum event in Washington, DC, and now this shows the continuing prioritization.

January 21, 2026 - This week, GSK announced its acquisition of RAPT Therapeutics—a move that has prompted renewed conversation about whether food allergy and anaphylaxis prevention are finally gaining sustained traction in pharma.